SCHEMBL2003499

SCHEMBL2003499

O=C(Cc1c[nH]c2ccccc12)Oc1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.68
MEN1 O00255 4/20 0.68
KMT2A Q03164 4/20 0.68
SMN1; SMN2 Q16637 3/20 0.68
ALDH1A1 P00352 2/20 0.68
LMNA P02545 1/20 0.68
HRH3 Q9Y5N1 4/20 0.67
PKM P14618 1/20 0.65
KDM4E B2RXH2 2/20 0.63
HPGD P15428 1/20 0.63
CYP1A2 P05177 1/20 0.63
CYP3A4 P08684 1/20 0.63
CYP2C19 P33261 1/20 0.63
FAAH O00519 2/20 0.61
SLC6A2 P23975 1/20 0.60
FNTA P49354 1/20 0.60
FNTB P49356 1/20 0.60
NR4A2 P43354 1/20 0.57
APAF1 O14727 1/20 0.51
POLB P06746 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9660764 0.90 HRH3 (0.64) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL9418839 0.89 HRH3 (0.67) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL11136651 0.86 MAPT (0.59) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL9659449 0.83 MEN1 (0.69) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL4781191 0.83 MAPT (0.74) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL27996401 0.83 HRH3 (0.58) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL11136033 0.82 PKM (0.69) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL21819729 0.82 HRH3 (0.58) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL13280575 0.82 MAPT (0.60) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL6965640 0.81 MAPT (0.72) MAPTMEN1KMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7964622-B2 Indole acetic acid derivatives and their use as pharmaceutical agents BAYER HEALTHCARE LLC (US) 2011-06-21 US disclosed
US-20090298854-A1 Indole acetic acid derivatives and their use as pharmaceutical agents MA XIN 2009-12-03 US disclosed
EP-1620088-A4 INDOLE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS BAYER PHARMACEUTICALS CORP (US) 2007-08-29 EP disclosed
EP-1620088-A2 INDOLE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS Bayer Pharmaceuticals Corporation (US) 2006-02-01 EP disclosed
WO-2004098498-A2 INDOLE ACETIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS BAYER PHARMACEUTICALS CORPORATION (US) 2004-11-18 WO disclosed
WO-1994000986-A1 PLANT GROWTH REGULATING COMPOSITIONS CHURCH & DWIGHT COMPANY, INC. (US) 1994-01-20 WO disclosed
US-4415350-A ROOTING; TREES THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF AGRICULTURE (US) 1983-11-15 US disclosed
US-4411684-A Auxin compositions of N-phenyl and N-chloro phenyl indolyl-3-alkylene amides and their use as auxin growth regulators THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 1983-10-25 US disclosed
US-4297125-A Tree rooting using synthetic auxins THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) 1981-10-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298854-A1 Indole acetic acid derivatives and their use as pharmaceutical agents IDO1, IDO2, AADAT MAPT 1349/4885MEN1 2247/4885KMT2A 1083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.